ECKARDT, J. N., F. STOLZEL, D. KUNADT, C. ROLLIG, S. STASIK, L. WAGENFUHR, K. JOHRENS, F. KUITHAN, A. KRAMER, S. SCHOLL, A. HOCHHAUS, M. CRYSANDT, T. H. BRUMMENDORF, R. NAUMANN, B. STEFFEN, V. KUNZMANN, H. EINSELE, M. SCHAICH, A. BURCHERT, A. NEUBAUER, K. SCHAFER ECKART, C. SCHLIEMANN, S. W. KRAUSE, R. HERBST, M. HANEL, M. HANOUN, U. KAISER, M. KAUFMANN, Zdeněk RÁČIL, Jiří MAYER, F. KROSCHINSKY, W. E. BERDEL, G. EHNINGER, H. SERVE, C. MULLER TIDOW, U. PLATZBECKER, C. D. BALDUS, J. SCHETELIG, M. BORNHAUSER, C. THIEDE and J. M. MIDDEKE. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. JOURNAL OF HEMATOLOGY & ONCOLOGY. LONDON: BMC, 2022, vol. 15, No 1, p. 1-13. ISSN 1756-8722. Available from: https://dx.doi.org/10.1186/s13045-022-01267-7.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
Authors ECKARDT, J. N. (guarantor), F. STOLZEL, D. KUNADT, C. ROLLIG, S. STASIK, L. WAGENFUHR, K. JOHRENS, F. KUITHAN, A. KRAMER, S. SCHOLL, A. HOCHHAUS, M. CRYSANDT, T. H. BRUMMENDORF, R. NAUMANN, B. STEFFEN, V. KUNZMANN, H. EINSELE, M. SCHAICH, A. BURCHERT, A. NEUBAUER, K. SCHAFER ECKART, C. SCHLIEMANN, S. W. KRAUSE, R. HERBST, M. HANEL, M. HANOUN, U. KAISER, M. KAUFMANN, Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), F. KROSCHINSKY, W. E. BERDEL, G. EHNINGER, H. SERVE, C. MULLER TIDOW, U. PLATZBECKER, C. D. BALDUS, J. SCHETELIG, M. BORNHAUSER, C. THIEDE and J. M. MIDDEKE.
Edition JOURNAL OF HEMATOLOGY & ONCOLOGY, LONDON, BMC, 2022, 1756-8722.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 28.500
RIV identification code RIV/00216224:14110/22:00126253
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/s13045-022-01267-7
UT WoS 000795132900001
Keywords in English Acute myeloid leukemia; Extramedullary; Leukemia cutis; Chloroma; Myeloid sarcoma
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/7/2022 09:00.
Abstract
Background Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed. Methods We retrospectively analyzed a large multi-center cohort of 1583 newly diagnosed AML patients, of whom 225 (14.21%) had EM. Results AML patients with EM presented with significantly higher counts of white blood cells (p < 0.0001), peripheral blood blasts (p < 0.0001), bone marrow blasts (p = 0.019), and LDH (p < 0.0001). Regarding molecular genetics, EM AML was associated with mutations of NPM1 (OR: 1.66, p < 0.001), FLT3-ITD (OR: 1.72, p < 0.001) and PTPN11 (OR: 2.46, p < 0.001). With regard to clinical outcomes, EM AML patients were less likely to achieve complete remissions (OR: 0.62, p = 0.004), and had a higher early death rate (OR: 2.23, p = 0.003). Multivariable analysis revealed EM as an independent risk factor for reduced overall survival (hazard ratio [HR]: 1.43, p < 0.001), however, for patients who received allogeneic hematopoietic cell transplantation (HCT) survival did not differ. For patients bearing EM AML, multivariable analysis unveiled mutated TP53 and IKZF1 as independent risk factors for reduced event-free (HR: 4.45, p < 0.001, and HR: 2.05, p = 0.044, respectively) and overall survival (HR: 2.48, p = 0.026, and HR: 2.63, p = 0.008, respectively). Conclusion Our analysis represents one of the largest cohorts of EM AML and establishes key molecular markers linked to EM, providing new evidence that EM is associated with adverse risk in AML and may warrant allogeneic HCT in eligible patients with EM.
PrintDisplayed: 10/7/2024 06:14